SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs admitted affair with a business executive and the Nvidia boards independent investigation have drawn attention, with traders debating whether the unverified espionage allegations and potential leadership fallout pose a serious risk or are an overreaction unrelated to Nvidias AI business. Many are buying the selloff on confidence in the companys fundamentals, while others remain cautious about the investigation and possible CEO succession concerns.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRX is selling off after a weaker-than-expected Q3 report, with traders focused on the revenue decline, slowing commercial uptake and possible future dilution. The reaction is mixed: critics question execution and the cash outlook, while bullish traders argue the positive BCG-naive trial result and Israeli approval support the longer-term Anktiva story.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

A sharp pre-earnings rally ahead of TTDs Q3 report has traders debating whether hopes for a turnaround and possible short covering are driving the move; others remain cautious given concerns about slowing growth and weak guidance.

Clover Health Investments Corp. is a physician enablement technology company, which engages in the provision of Medicare Advantage plans in the United States. Its strategy is powered by its proprietary software platform, Clover Assistant, which aggregates patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic diseases. The company offers PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on its flagship wide-network, high-choice PPO plans. The company was founded by Vivek Garipalli and Andrew Toy on July 17, 2014 and is headquartered in Wilmington, DE.

Clover Health Investments Corp - Ordinary Shares - Class A

Clover Health Investments Corp

Clovers Q3 earnings beat and improved full-year outlook, alongside a profitable quarter and strong membership growth, are fueling renewed buying and a push to hold above $5. Traders are divided over whether the gains can stick, with some focused on the companys growth and others disappointed by the lack of concrete Counterpart Health software revenue updates.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims is in focus ahead of its quarterly results as traders weigh the Eli Lilly agreement to offer branded obesity drugs through its platform against concerns that the shift could pressure margins. The sharp decline has fueled speculation about disappointing results or an earnings leak, while others see the partnership and potential growth as reasons to stay bullish.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics BRIUMVI-driven quarterly beat and raised revenue outlook are drawing attention, but shares have fallen as traders debate a sell-the-news reaction versus a buying opportunity. The upcoming Phase 3 readout for subcutaneous BRIUMVI is widely viewed as the next major catalyst.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Jefferies Buy initiation and favorable Phase III prostate cancer data are drawing attention to Candels planned BLA filing for CAN-2409. Bulls see the results and recent immune-profile data as support for the regulatory case, while skeptics question filing execution, manufacturing readiness, financing needs and management transparency.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Debate over allegations of Webulls China ties and the fallout from a congressional report and securities lawsuits dominates discussion, with traders attributing the stocks weakness to a lingering China-related risk discount. Some see the upcoming earnings report and the companys growth as potential confidence builders, while skeptics say the overhang and poor performance versus peers remain unresolved.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Traders are linking ARWRs sharp decline to weak early sales for rival Ioniss Tryngolza, raising concerns about the commercial outlook for Arrowheads Redemplo despite some arguing its data and product profile are stronger. Others point to Arrowheads high cash burn and possible financing needs as added pressure.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs stronger-than-expected quarterly results and raised full-year revenue outlook are driving attention, with traders also pointing to expanding backlog and quantum-computing demand. Bulls see evidence of commercial momentum, while skeptics question dilution, cash burn and how much growth came from the SkyWater acquisition, keeping the reaction volatile.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TG Therapeutics’ CEO Sees Global Revenue Exceeding $1B In 2026 – BRIUMVI Drives Q3 Topline Beat

The decline appears tied to post-earnings selling: revenue beat estimates and 2026 guidance rose to about $1 billion, but EPS of $0.35 narrowly missed the $0.36 consensus. Traders also pointed to sell-the-news pressure after the report.

Equity

TG Therapeutics reported Q3 revenue of $259.9 million, beating Wall Street’s estimate of $245.5 million, according to Fiscal.ai.


TG Therapeutics (TGTX) Beats Q3 Earnings and Revenue Estimates

TG Therapeutics (TGTX) delivered earnings and revenue surprises of +25.00% and +5.17%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance

TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2026, along with recent company developments and provided an update on 2026 financial guidance. Michael S. Weiss, Chairman and Chief Executive Officer of TG...

Biotech Beats SPY And QQQ In Market Rout — Now Hims Earnings And Summit’s FDA Test Take Center Stage 

Hims & Hers will report results on Monday after its Lilly agreement expanded access to Zepbound and Foundayo.

Intellia's Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus

NTLA's Q3 loss deepens, while progress on its lonvo-z & nex-z clinical programs & a $400 million loan facility strengthen its pipeline & financial flexibility.

Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock Down

AGEN's Q3 earnings meet estimates, but a revenue miss weighs on shares as pipeline progress, Armenian drug approvals and new funding emerge as key developments.

IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs

Iovance beat Q3 2026 earnings and revenue estimates as Amtagvi sales top $100 million, margins improve and R&D costs decline.

HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix Growth

Harmony Biosciences' Q3 earnings missed estimates as higher costs weighed on profits, while Wakix demand and pipeline progress supported its 2026 revenue outlook.

ZTS Q3 Earnings Top Estimates, 2026 Profit Outlook Improves, Stock Up

Zoetis beats third-quarter earnings and revenue estimates. Livestock sales growth partially offsets weakness in companion animal products.

Viatris Q3 Earnings Beat on Stronger Margins, Revenues Fall Y/Y 

VTRS beats Q3 earnings estimates on stronger margins and raises 2026 earnings guidance, despite revenue miss and persistent supply constraints.

$TGTX Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of $0.35 down -85.60% YoY
• Reported revenue of $259.94M up 60.74% YoY
• TG Therapeutics raised full-year 2026 total global revenue guidance to approximately $1B and BRIUMVI U.S. net product revenue guidance to approximately $915.92B; operating expense guidance remains approximately $450.5B, excluding non-cash compensation.

Stocktwits

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of $0.35 down -85.60% YoY
• Reported revenue of $259.94M up 60.74% YoY
• TG Therapeutics raised full-year 2026 total global revenue guidance to approximately $1B and BRIUMVI U.S. net product revenue guidance to approximately $915.92B; operating expense guidance remains approximately $450.5B, excluding non-cash compensation.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

• Reported GAAP EPS of $0.35 down -85.60% YoY
• Reported revenue of $259.94M up 60.74% YoY
• TG Therapeutics raised full-year 2026 total global revenue guidance to approximately $1B and BRIUMVI U.S. net product revenue guidance to approximately $915.92B; operating expense guidance remains approximately $450.5B, excluding non-cash compensation.

TG Therapeutics reported increased R&D and SG&A expenses, disclosed third-party manufacturing and supply risks, and cautioned that subcutaneous BRIUMVI may fail clinically, lack approval, or not achieve commercial acceptance.

TG Therapeutics reported a year-over-year BRIUMVI U.S. revenue increase, positive ENHANCE results supporting single-infusion initiation, and seven-year data showing ARR of 0.018 and 88.3% remaining free from 24-week confirmed disability progression.

TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.

Bullish Sentiment

<ul class="summary-bullets"><li>The company raised its FY 2026 U.S. Briumvi sales forecast to $915 million to $920 million.</li><li>TG Therapeutics expects results of its Phase 3 subcutaneous Briumvi trial by the&nbsp;end of the&nbsp;year or Q1 2027.</li><li>The biotech ended September with $556.7 million in cash, cash equivalents, and investment securities.</li></ul>TG Therapeutics (TGTX) was in the spotlight on Monday after the biotech firm reported a better-than-expected third-quarter topline and raised its full-year 2026 global revenue forecast, driven by strong growth in its multiple sclerosis (MS) treatment, Briumvi.<a class="mention" data-mention="$TGTX" data-symbol-id="TGTX" href="https://stocktwits.com/symbol/TGTX" target="_blank">TGTX shares</a> were up around 2% at the time of writing.<h2 class="st-heading-2">Briumvi Sales Drive Q3 Revenue Beat</h2>CEO Michael Weiss said the company is on track to exceed $1 billion in annual revenue and is well positioned for long-term growth.“With solid third-quarter performance and a strong fourth quarter anticipated, we are on track to exceed $1 billion in global revenue in 2026, less than four years after launching Briumvi,” Weiss said.“With continued momentum in our IV business, the potential to expand the Briumvi franchise through new dosing options, and a growing pipeline of development opportunities, we believe we are laying the foundation for sustained, long-term growth.”TG Therapeutics reported Q3 revenue of $259.9 million, comfortably beating Wall Street’s estimate of $245.5 million, according to Fiscal.ai. A 52% increase in Briumvi net product revenue led the outperformance. Diluted earnings per share (EPS) came in at $0.35, slightly below the consensus estimate of $0.36.The company also raised its full-year 2026 U.S. Briumvi sales forecast to $915 million to $920 million from its earlier forecast of $890 million to $905 million.<h2 class="st-heading-2">Phase 3 Subcutaneous Briumvi Results Expected Latest By Q1 2027</h2>While Briumvi is already FDA-approved as an intravenous infusion for adults with relapsing forms of MS, TG Therapeutics is developing a subcutaneous version that could allow patients to receive treatment at home.The fully enrolled Phase 3 trial compares injections given every two or three months against the approved intravenous treatment, which is administered at a six-month interval after initial doses. The company expects Phase 3 results either this year or by Q1 2027, with a potential commercial launch in 2028.The company ended September with $556.7 million in cash, cash equivalents, and investment securities. Along with the projected revenues from Briumvi, TG Therapeutics expects funds to be sufficient to run its current operating plan.<h2 class="st-heading-2">Retail’s Take TGTX</h2>Retail sentiment for TGTX on Stocktwits remained ‘bullish’ over the past 24 hours. TGTX was also among the top trending tickers on the platform at the time of writing.<img src="https://news.stocktwits-cdn.com/TGTX_d75a95feac.png" alt="TGTX.png">One user expects the stock to climb to triple digits after the Phase 3 Briumvi subcutaneous data.<stembedurl>https://stocktwits.com/Bio_investor_/message/668551359</stembedurl>TGTX shares have seen strong buying interest so far in 2026, surging more than 104%.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/stifel-sees-opportunity-for-spacex-in-stalled-data-center-projects-flight15-launch/cNGrBzSR9es">&nbsp;Stifel Sees Opportunity For SpaceX In Stalled Data Center Projects — Reiterates ‘Buy’ Ahead Of Flight 15</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the TG Therapeutics logo is displayed on the screen of a smart tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

TG Therapeutics reported Q3 revenue of $259.9 million, beating Wall Street’s estimate of $245.5 million, according to Fiscal.ai.

SPDR S&P Biotech ETF

Buying the dip

Selling or trimming

Holding

Waiting for the investigation results to decide

Nvidia ($NVDA) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Stocktwits Polls

Investors are eagerly anticipating Monday's Q3 results, focusing on BRIUMVI sales growth and a raised revenue guidance.

Traders are closely watching for a short squeeze as high short interest conflicts with strong commercial momentum.

The upcoming subcutaneous data readout is being flagged as the primary driver for long-term valuation and potential M&A.

Many retail longs are treating the recent volatility as an accumulation opportunity, adding positions despite broader market selling.

Conviction remains high that the commercial success of BRIUMVI makes the company a prime buyout target for major pharmaceutical players.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$0.45	--	--	N/A
Q3 '26	$0.37	$0.35	-4.58%	MISSED
Q2 '26	$0.31	$0.05	-83.64%	MISSED
Q1 '26	$0.28	$0.12	-56.44%	MISSED
Q4 '25	$0.35	$0.14	-60.28%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

TGTX Earnings

Latest Earnings Results: Q3 '26

Historical Earnings